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Objective: In breast diffusion-weighted imaging (DWI),
the apparent diffusion coefficient (ADC) is used to
discriminate between malignant and benign lesions. As
ADC estimates can be affected by the weighting factors,
our goal was to determine the optimal pair of b-values for
discriminating breast lesions at 3.0T.
Methods: 152 females with 157 lesions (89 malignant
and 68 benign) underwent breast MRI, including a DWI
sequence sampling six b-values 50, 200, 400, 600, 800
and 1000 smm22. ADC values were computed from
different pairs of b-values and compared with ADC
obtained by fitting the six b-values using a mono-
exponential diffusion model (ADCall). Cut-off ADC
values were determined and diagnostic performance
evaluated by receiver operating characteristic analysis
using Youden statistics. Mean ADCs were determined
for normal tissue and lesions. Differences were evalu-
ated by lesion and histological types.
Results: Considering the cut-off values 1.46 and
1.493 103mm2s21, the pairs 50, 1000 and 200, 800smm22
showed the highest accuracy, 77.5% and 75.4% with areas
under the curve 84.4% and 84.2%, respectively. The best
pair forADCquantificationwas50, 1000smm22with38/49
true-negative and 69/89 true-positive cases respectively;
mean ADCs were 1.866 0.46, 1.776 0.37 and 1.156
0.4631023mm2s21 fornormal,benignandmalignant lesions.
There were no significant differences in these ADC values
when comparedwithADCall (ADCcalculated from the full set
ofb -values) [difference50.007531023mm2s21; confidence
interval 95%: (20.0036; 0.0186); p50.18].
Conclusion: The diagnostic performance in differentiat-
ing malignant and benign lesions was most accurate for
the b-value pair 50, 1000smm22.
Advances in knowledge: The best b-value pair for lesion
discrimination and characterization through ADC quanti-
fication was 50, 1000smm22.
Over the past years, MRI has been used to study breast
lesions,1–3 with clinical recommendations established for its
application.4–6 Interpretation of conventional breast MRI is
based on morphological and kinetic descriptors.7 However,
sometimes lesions present features that limit accurate char-
acterization and diagnostic performance. The use of diffusion-
weighted imaging (DWI) has helped to overcome this limita-
tion, with improved specificity and accuracy for lesion de-
tection and discrimination,8,9 especially when combined with
dynamicMRI.10,11 To evaluate water mobility in normal breast
tissue and lesions, the apparent diffusion coefficient (ADC) can
be quantified from the signal intensity (SI) loss between two or
more b-values.12,13 ADC calculation is based on the logarithmic
transformation of the SI loss over time, expressed by ADC5
21/(b22b1) log (Sb2/Sb1), where Sb1 and Sb2 represent the
SI measured for b-values b1 and b2, respectively.14
ADC estimates are expected to become more accurate as the
number of b-values increases.14 However, a study by Bogner
et al15 showed only minor improvement in ADC precision
when the number of b-valueswas increased from two up to ten.
Given that the acquisition time is proportional to the number
of b-values, a compromisemust be sought tominimize it while
maintaining adequate ADC precision. Another issue to con-
sider is that the echo-time (TE) increases with the highest
b-value used, resulting in a lower signal-to-noise ratio (SNR)
owing to transverse relaxation.
The typical highly cellular composition of malignant lesions
impedes water mobility,16 and so they should exhibit a higher
SI on DWI and a lower ADC value than benign lesions.17,18
However, it is important not to neglect the intrinsic T2
weighting of diffusion images. A tissue change that has a longer
or shorter T2 relaxation would also lead to an increased or decreased
SI (respectively), which could erroneously be interpreted as being
related to changes in diffusion properties. Prolonged T2 values in
certain tissues, such as water in cysts, cause a T2 shine through effect
on DWI, whereas T2 shortening results in T2 blackout effects.
14,19,20
To avoid these confounds, it is essential to compute quantitative ADC
maps and use them to analyse the areas with high SI on high b-value
images as stated by Koh and Collins14.
In the case of simple cysts, ADC is increased because restriction to
water mobility is scarce owing to low cellularity.8 In comparison,
complex cysts present proteins and blood in their matrix that lead
to a low ADC.13 Finally, benign lesions have higher ADC than
malignant ones because of their less compact celullarity.17,21
Le Bihan et al22 attributed SI differences in lesions to changes in the
intra- and extracellular compartments’ architecture and to modi-
fied microcirculation, which can be affected as a result of the
neovascularization process allied to solid lesion growth. The SI loss
related to microcirculation, which results from intravoxel in-
coherent motion (IVIM), can be estimated by including low b-
value images and a bi-exponential model23,24 to account for this
“pseudo-diffusion coefficient”. Since this coefficient is typically an
order of magnitude higher than the diffusion coefficient, the im-
pact of IVIM should be consideredwhen choosing theminimum b-
value. For a sufficiently high minimum b-value, the perfusion
contribution may be ignored and a mono-exponential model used
to describe the data. As for the highest b-value, it should be chosen
so as to provide adequate suppression of water signal from normal
fibroglandular tissue and maximum breast lesion visibility.23
As far as we are aware, the post-processing software available on
clinical scanners employs a mono-exponential model to fit the SI
decay.14 This model does not account for perfusion, which means
that the estimated ADC value will be affected by the perfusion
fraction to a degree that depends on the choice of the b-values.
In addition, a recent meta-analysis25 highlighted the fact that
there is no standard set of b-values to discriminate benign from
malignant lesions. Some studies combined low 0 or 50 smm22
and high 1000–1500 smm22 b-values,15,25 whereas others used
a larger set of b-values to calculate the ADC.26,27 The use of
b5 800 smm22 and higher seems to increase the sensitivity
for lesion differentiation.27,28 However, ADC thresholds are
highly variable in the literature, ranging from 1.10 to
1.613 1023 mm2 s21.25 Several factors may contribute to that,
such as lesion heterogeneity between the samples; different
field strengths and acquisition protocols across the studies
(including b-values); and image analysis procedure including
region of interest (ROI) size and delineation criteria.18,26,29
The purpose of our study was to identify the optimal pair(s) of b-
values, for which the estimated ADC shows the best accuracy for
lesion discrimination at 3.0 T, aiming tominimize acquisition time.
METHODS AND MATERIALS
Subjects and lesions
A prospective study was conducted between July 2009 and Oc-
tober 2012. All females with clinical indication for breast MRI
who fulfilled the inclusion criteria were asked to participate in
this study. Data presented here are included in a wider in-
vestigation, and the study has received approval from the Ethics
Committee of Hospital São João, Porto, Portugal [protocol:
Comissão de Etica para a Sau´de (CES) 276/13]. Written in-
formed consent was obtained from all patients.
Within this period, 219 breast MRI examinations (182 consecu-
tive patients) were performed. 30 patients were evaluated more
than once. Clinical indications to perform breast MRI included
pre-operative evaluation, pre- and post-neoadjuvant chemo-
therapy, positive surgical margins, post breast conservation, un-
known primary malignancy, breast cancer screening, equivocal
mammographic and/or ultrasound features, therapeutic moni-
toring, follow-up after surgery and breast cancer recurrence.
Exclusion criteria were (1) patients undergoing chemotherapy
or/and radiotherapy at the time of the examination or having
received treatment within a period shorter than 24 months
(n5 8); (2) having been submitted to surgery within less than 6
months (n5 10); (3) having finished hormone replacement
therapy within less than 24 months (n5 5); (4) having breast
implants (n5 2); and (5) females whose images evidenced rel-
evant motion artefacts (n5 5) during the examination.
Lesions were included in the DWI analysis if (1) the minimum size
was $0.7 cm in dynamic contrast-enhanced (DCE) MRI; (2)
proven histological result was available; and (3) females had pre-
vious 2-year follow-up with mammography, ultrasound or MRI.
For the pre-menopausal females, the MR examination was per-
formed between the 7th and the 14th day of the menstrual cycle to
minimize the enhancement on the fibroglandular tissue owing to
gadolinium injection.30 For females who had undergone needle
biopsy, aminimum interval of 10 days before theMRI examination
was imposed to reduce potential SI changes due to haemorrhages
and/or oedema. Finally, simple cysts were excluded and ignored, as
their high ADC would have lead to a bias in the results, increasing
ADC values of the benign lesions group.
Acquisition protocol
The examinations were performed using a 3.0T system (MAGNE-
TOM® Trio Tim System; Siemens Healthcare, Erlangen, Germany)
equipped with a dedicated four-channel phase-array coil (Invivo
Corporation, Orlando, FL). Patients rested in the prone position.
Table 1 presents the main parameters of the scanning protocol.
DWI was performed before the DCE pulse sequence with the
sensitization gradients applied in the x, y and z directions to gen-
erate three-scan-trace images. Eight b-values were sampled 50, 200,
400, 600, 800, 1000, 2000 and 3000 smm22. In this study, we
limited the analysis to the range of b-values for which the as-
sumption that water diffusion follows a Gaussian distribution can
be considered to be valid; the b-values included in the analysis
therefore ranged from 50 to 1000 smm22 and amono-exponential
fitting of the signal was performed.31 For the higher b-values 2000
and 3000 smm22, a non-Gaussian model needs to be considered32
and so ADC quantification using a mono-exponential fitting in-
corporating these values would not have been appropriate.
Image analysis
All the images were processed in the scanner workstation (Syngo®
Multimodality, Siemens Healthcare) using the commercial soft-
ware (Syngo MR V17A, work in progress). Conventional MRI
data were interpreted using the Breast Imaging Reporting and
Data SystemMRI.7 Lesion size was measured on the DCE images
considering its highest dimension using the ruler function.
Two researchers retrospectively analysed the diffusion-weighted (DW)
images in consensus. At the timeofDWIanalysis, readerswere blinded
to histological results. Each lesionwas drawn in the DW images based
on the MRI report and using T2 weighted, early subtracted DCE and
the post-contrast images, serving as a roadmap to place the ROI. The
slice showing the lesion’s highest dimension and the best definition of
itsmargins was selected. Tomeasure lesion SI for each b-value, images
at b5400 smm22 were selected and 0.25 cm2fixed size ROI drawn in
the most hyperintense area of the lesion and then copied to all others.
When using this b-value, the contrast between the lesion core and its
outer limits is still high, facilitating ROI placement. ROIs were drawn
avoiding areas of fibroglandular tissue, as well as necrotic and cystic
areas. In females with unilateral lesions, the normal glandular tissue
ROIwas drawn in the contralateral breast. ROIswere also placed using
b5400 smm22 images. Mean value and standard deviation of the SI
within the ROI were recorded for each b-value.
Apparent diffusion coefficient quantification
For normal tissue and lesions, the ADC maps were calculated
using (a) the six b-values 50, 200, 400, 600, 800, 1000 smm22 and
(b) considering different pairs of b-values minimum b-value was
50, 200 or 400 smm22.
When using the six b-values, the ADC values (ADCall) were
determined by fitting the linearized version of the mono-
exponential model to the data,33 using the program Excel®
(Microsoft, Redmond, WA):
SðbÞ5 S0expð2ADCall×bÞ⇒ln½SðbÞ5ln½S02ADCall×b (1)
where S0 is the MRI signal without diffusion-weighted sensiti-
zation (b5 0 smm22), and S(b) represents the SI measured for
each b-value.
When only a pair of b-values was used, the ADC was estimated
for the nine resulting combinations, using Equation (2):
ADC5
ln½Sðb1Þ2 ln½Sðb2Þ
b22 b1
(2)
where b1 and b2 were the two b-values considered.
Additionally, for each lesion, the relative difference (Drel) in the
ADC value was calculated for each pair of b-values as:
Drel5
jADC2ADCallj
ADCall
(3)
Statistical analysis
A descriptive analysis was performed, by patients and lesion types.
For each b-value combination, mean ADC values were computed
Table 1. Scanning MRI protocol
Parameters Conventional pre-contrast DWI-SPAIR Dynamic Post-contrast
Sequence T2W TSE
T1W 3D
FLASH
T2W TSE Single-shot EPI
T1W 3D
FLASH
T1W 3D
FLASH
Orientation
Axial
bilateral
Sagittal Sagittal Sagittal
Axial
bilateral
Sagittal
Repetition time/echo
time (ms)
4990/88 17/4.9 4920/67 4900/106 3.77/1.42 7.8/3.9
Inversion time (ms) – – 210 – – –
Fat suppression – – STIR SPAIR SPAIR Water excitation
Field of view (mm2) 3203 320 2003 200 2003 200 2503 250 3203 320 1603 160
Matrix 5123 384 2753 384 4483 314 843 128 3583 448 2563 256
Slice thickness 4 2 4 5 0.9 0.9
Number of slices 26 64 26 16 160 144
Number of excitations 2 1 2 3 1 1
Bandwidth (Hz per
pixel)
305 430 248 1628 490 450
Scan time (min) 2:06 3:49 4:26 5:58 4:32 3:12
b-values (smm22) – – –
50, 200, 400, 600, 800, 1000, 2000
and 3000
– –
3D, three dimensional, DWI-SPAIR, diffusion-weighted imaging with spectrally adiabatic inversion–recovery; EPI echo-planar imaging; T1 3D FLASH,
three dimensional gradient echo fast low angle shot; T1W, T1 weighted; T2 W, T2 weighted; TSE, turbo spin echo; STIR, short tau inversion recovery.
for normal tissue and solid benign and malignant lesions. The
Kolmogorov–Smirnov test was used to verify the normality of the
data. The Mann–Whitney test was used to assess the differences in
ADC values between lesion type (benign and malignant) and
between normal tissue and malignant and benign lesions.
The best pairs of b-values were identified as the combinations
that showed a Drel , 6%. It was also considered imperative that
the corresponding ADC values showed no significant statistical
difference when compared with ADCall. The pair combinations
of b-values that did not fulfil both criteria were excluded from
the analysis. The Wilcoxon test was used to compare ADCall with
the ADC values estimated from b-value pairs.
The ADC cut-off for the candidate’s b-value combinations and
ADCall were calculated considering Youden statistics and the
minimal distance between the receiver operating characteristic
(ROC) curves and the ideal point of coordinates (0, 1), where
both the sensitivity and specificity have a maximum value of 1.
For the best b-value pairs, false-positive and false-negative, true-
positive and true-negative rates were calculated. Wilcoxon
signed-rank test (paired sample) was used to compare ADC
values by histological type for the best pair combinations.
Data were analysed using the PASW® Statistics v. 20 software
(Hong Kong), with statistical significance set at p, 0.05.
RESULTS
Subject and lesion characteristics
152 females with 157 lesions met the inclusion criteria for image
analysis. The mean patient age was 49.16 2.5 years (range,
21–82 years). 83 patients were pre-menopausal.
From the 157 lesions, 83 were diagnosed by surgical excision and
38 by needle biopsy, while 36 were accepted to be benign and
classified based on the morphological/kinetic features and di-
mensional stability as observed by mammography, ultrasound
and/or MRI during a 2-year follow-up. 89 lesions were classified
as malignant: 9 ductal carcinoma in situ (DCIS), 47 invasive
ductal carcinoma (IDC), 4 lobular carcinoma in situ, 20 invasive
lobular carcinoma (ILC), 1 mucinous carcinoma and 8 other
malignant lesions not otherwise specified (NOS).
68 lesions were benign and included: 24 fibroadenomas (FAs), 7
epithelial proliferative lesions (EPLs), 3 papillomas (PAs), 19
cysts (Cs), 2 hamartomas (HAs) and 13 other benign lesions
[fibrocystic changes (FCs), complex sclerosing adenosis (CSA)
and complex cyst lesion]. 36 of these benign lesions were eval-
uated by follow-up and included 9 FAs; 1 EPL, 2 HAs, 8 FCs
and 16 cysts. All simple cysts were excluded from the final
analysis.
Themean size for benign andmalignant lesionswere 15.4611.4mm
and 22.2613.7mm, respectively, ranging from 7 to 78mm.
ADC values and differences by tissue type
Table 2 illustrates the descriptive analysis for the mean ADC in
normal tissue and solid benign and malignant lesions for all the
combinations studied and differences in ADCs between tissue
types for each combination of b-values.
Results showed significant differences in the ADC between be-
nign and malignant lesions (p, 0.001). For all the b-value
combinations, malignant lesions showed lower ADC values
when compared with benign ones.
Determination of the best pair of b-values
Table 3 summarizes the statistics for determining the best pair of b-
values, including Drel averaged among all lesions and comparison
between ADCall and ADC values estimated from the b-value pairs.
The pairs 50, 800; 50, 1000; 200, 800 and 200, 1000 smm22 showed
the lowest Drel (the sum of their relative frequencies was 79%),
corresponding to a Drel, 6%. Although, the pairs 50, 800 and 200,
1000 smm22 presented a low variability withDrel, 6%, significant
differences were found when comparing the ADC values estimated
with ADCall and, for this reason, these pairs were excluded from
subsequent analysis.
The combination 50, 1000 smm22 provided the best results,
with a mean Drel, 3% and no significant differences in the ADC
when compared with ADCall (p5 0.152). The ADC calculated
from the pair 200, 800 smm22 also showed no significant dif-
ferences relative to ADCall (p5 0.866), but displayed higher
mean Drel (5.2%).
Diagnostic accuracy for the optimal pairs of b-values
The ADC cut-offs (for solid benign and malignant lesions) using
ADCall, 50, 1000 and 200, 800 smm
22 were calculated to assess
sensitivity and specificity. Figure 1 presents the ROC curves for
the best b-value combination and ADCall.
To compare the performance of each pair for lesion discrimi-
nation once an ADC cut-off had been established, their sensi-
tivity, specificity, false and true rates were calculated (Table 4).
Regarding the two tested pairs, 50, 1000 smm22 showed the
highest accuracy (77.5%; AUC5 84.4%), followed by 200,
800 smm22 (75.4%; AUC5 84.2%).
The pair 50, 1000 smm22 showed the lowest number of false-
negative and false-positive cases. False-negative cases were pre-
dominantly IDC with in situ component and necrosis areas (7),
ILC (8), DCIS (3) and other malignant NOS (2). Inspecting the
lesion sizes, for the false-negative cases, these ranged from 18 to
29mm for IDC, ILC ranging from 12 to 18mm, DCIS ranged
from 9 to 12 mm and NOS with 18 and 25mm.
False-positive cases were 1 PA, 6 FA, 2 CSA and 2 EPL with
fibroblastic/miofibroblastic component. The largest dimension
for the PA was 8mm with FA ranging from 8 to 15mm. The
sizes of the remaining false-positive lesions were of 9 and 10mm
for CSA and 9 and 11mm for the two EPL.
Figure 2a–c presents the ADC distribution for the lesion type
and normal glandular tissue for ADCall and the two best pairs of
b-values.
Comparison between apparent diffusion
coefficient values
Mean ADC values from the b-values pairs were compared by
lesion histological type (Table 5).
For these combinations of b-values, there were no differences
between the mean ADC of solid lesions when considering the
different histological types.
Figure 3 illustrates a case of a 41-year-old female with a IDC, Grade
III and includes sagittal short tau inversion recovery (a), DCE (b),
DWI with b-value 1000 smm22 (c) and the ADC map (d).
DISCUSSION
Reports15,26 focussing on the best pair of b-values to discrimi-
nate and characterize breast lesions, particularly when using
3.0 T scanners are scarce. Previous studies34,35 using few b-values
(two or three at the most) have reported maximum b-values for
ADC quantification ranging from 600 to 800 smm22. Others
suggested that more accurate ADC measurements can be ach-
ieved by using multiple b-values.8,36 However, in clinical prac-
tice, time constraints prevent their use, as acquisition time
would otherwise be prolonged. Therefore, it is important to
identify a smaller set of b-values that enables accurate ADC
quantification within a reasonable acquisition time.
Table 2. Apparent diffusion coefficient (ADC) values for normal tissue, solid benign and malignant lesions vs b-value combinations
and differences for each pair combination between tissue types
b-values
(smm22)
ADC value (31023mm2 s21) for each tissue type
p-valuec p-valuea p-valuebNormala,b,
mean6 SD
Benignc,a,
mean6 SD
Malignantc,b,
mean6 SD
50–1000d 1.876 0.47 1.786 0.37 1.156 0.47 ,0.001 0.01 ,0.001
50, 200 1.866 0.41 1.866 0.76 1.386 0.61 ,0.001 0.92 ,0.001
50, 400 1.836 0.40 1.906 0.44 1.316 0.54 ,0.001 0.17 ,0.001
50, 600 1.806 0.42 1.816 0.44 1.266 0.49 ,0.001 0.37 ,0.001
50, 800 1.766 0.38 1.816 0.37 1.206 0.48 ,0.001 0.05 ,0.001
50, 1000 1.866 0.46 1.776 0.37 1.156 0.46 ,0.001 0.03 ,0.001
200, 600 1.786 0.43 1.796 0.48 1.226 0.48 ,0.001 0.24 ,0.001
200, 800 1.746 0.39 1.806 0.39 1.166 0.47 ,0.001 0.08 ,0.001
200, 1000 1.796 0.47 1.766 0.39 1.116 0.45 ,0.001 0.39 ,0.001
400, 1000 1.716 0.70 1.706 0.38 1.066 0.45 ,0.001 0.74 ,0.001
SD, standard deviation.
a
p-value differences in ADC values between normal tissue and solid benign lesions (Mann–Whitney test).
b
p-value differences in ADC values between normal tissue and solid malignant lesions (Mann–Whitney test).
c
p-value differences in ADC values between solid benign and malignant lesions (Mann–Whitney test).
d
ADCall six b-values ranging from 50 to 1000smm
22.
Table 3. Relative differences of lesion apparent diffusion coefficient (ADC) values and comparison between ADC values calculated
using pairs of b-values and ADCall
b-values (smm22) Mean Drel (%)
a Absolute frequencyb Relative frequency (%)c p-valued
50, 200 27.5 4 2.6 ,0.001
50, 400 16.8 3 1.9 ,0.001
50, 600 10.4 6 3.8 ,0.001
50, 800 5.0 23 14.7 ,0.001
50, 1000 2.9 46 29.3 0.152d
200, 600 8.9 15 9.6 ,0.001
200, 800 5.2 27 17.2 0.866d
200, 1000 4.6 28 17.8 ,0.001
400, 1000 9.2 5 3.2 ,0.001
a
Mean Drel: relative difference between ADC and ADCall with respect to ADCall, averaged among all lesions.
b
Absolute frequency: number of lesions for which the ADC value estimated from a particular b-value pair is closest to ADCall (smallest Drel).
c
Relative frequency: absolute frequency/total number of lesions.
d
p-value .0.05—no statistical differences between ADC values estimated with the indicated pair and ADCall.
Our results were consistent with previous studies on lesion
differentiation.8,37 The ADC values for malignant lesions were
lower than benign ones. The pair 50, 1000 smm22 provided the
ADC estimate closest to ADCall. Sensitivity, specificity and accuracy
were high (77.5%, 77.6% and 77.5%, respectively), with a proba-
bility of a correct diagnosis of 84.4% and the lowest ADC overlap
between lesions. The ADC cut-off was 1.463 1023 mm2 s21,
which is in the range of what was previously reported, although
slightly higher when compared with studies using similar pairs of
b-values.25,38 Using the pair 50, 1000 smm22, mean ADC values
were 1.8660.4631023mm2s21 for normal glandular tissue; 1.776
0.3731023mm2s21 for benign and 1.1560.4631023mm2s21
for malignant lesions.
Other studies concerning the identification of the best b-values for
breast lesion discrimination were previously performed at 3.0T.15,26
Peters et al26 used the b-values 0, 150, 499, 1500 smm22 consid-
ering five different combinations to measure the diffusion and
Figure 1. Receiver operating characteristic curves when considering b-values 50–1000, 50, 1000 and 200, 800smm22.
Table 4. Diagnostic accuracy when using apparent diffusion coefficient (ADCall) or the ADC estimated from the pairs of b-values 50,
1000 and 200, 800smm22
Performance metrics
b-values pair combinations (smm22)
50–1000 50, 1000 200, 800
ADC cut-off (31023mm2 s21) 1.47 1.46 1.49
Sensitivity (%) 77.5 77.5 76.4
Specificity (%) 75.5 77.6 73.5
Accuracy (%) 76.8 77.5 75.4
AUC (%) 84.5 84.4 84.2
AUC (95%) 77.3–90.0 77.3–90.0 77.1–89.9
False negative 20 20 21
False positive 10 11 13
True negative 58 57 55
True positive 69 69 68
AUC, area under the curve.
AUC (95%) indicates the corresponding 95% confidence interval.
perfusion components. They found that the use of lower or higher
b-values affects ADC estimates, but not DWI diagnostic
performance.
In a similar work, Bogner et al15 used b-values (0, 50, 100, 250,
400, 550, 700, 850, 1000 and 1250 smm22) and compared sets of
pairs. The pair with best accuracy (95%) was 50, 850 smm22,
with similar diagnostic precision to the full b-value set. The ADC
values we obtained with 50, 1000 smm22 were similar for normal
tissue (Bogner et al:15 1.886 0.243 1023mm2 s21 and the
present study: 1.866 0.463 1023mm2 s21) and malignant
lesions (Bogner et al:15 1.006 0.183 1023mm2 s21 and the
present study: 1.156 0.463 1023mm2 s21), with a larger dif-
ference seen for benign lesions (Bogner et al:15 1.506 0.273 102
3mm2 s21 and the present study: 1.776 0.373 1023mm2 s21),
potentially owing to differences in the specific studied lesions.
In a study developed by Matsuoka et al,39 malignant lesions in
the same patient group were imaged at 3.0 T and 1.5 T; lesions
were classified according to their size as large (.10mm) or
small (#10mm). They found that there were no differences in
ADC values, which is in agreement with the knowledge that the
magnetic field strength has no influence in ADC values. How-
ever, visibility in the small lesion group was better at 3.0 T than
at 1.5 T, owing to increased SNR and spatial resolution. The mean
size of the small lesion group was 6.4mm (range, 3–10mm). For
this reason, and to ensure appropriate visibility for lesion de-
marcation and ADC quantification, only lesions with at least
7-mm diameter were included in the present study. Since Peters
et al26 andMatsuoka et al39 claimed to be able to diagnose tumour
lesions with 4 and 3mm, respectively, using 3.0 T MRI scanners,
future studies should test this possibility further and include also
smaller lesions in the analysis.
False-positive lesions in this study measured between 8 and 15mm
and comprised 1 PA; 6 FA; 2 CSA; and 2 EPL with fibroblastic/
miofibroblastic component. Their small size relative to the voxel
dimensions may have impaired their characterization with DWI.
Figure 2. Box plots for apparent diffusion coefficient (ADC) values (31023mm2s21) for lesion type and normal glandular tissue for
ADCall (a), 50, 1000smm
22 (b) and 200, 800smm22 (c). The horizontal lines represent the corresponding ADC cut-off values for
differentiating between benign and malignant lesions.
Another possible explanation for the false-positive cases is the
presence of fibrotic tissue, proliferation and the degree of celul-
larity, which restricts water movement and results in lower ADC
values. These findings are consistent with other studies.13,40,41
False-negative cases were IDC with in situ component, highly
spread ILC, DCIS and NOS lesions. All these lesions measured
between 9 and 29mm. These results could be related to partial
volume effects, specially the ILC owing to the spread of these
lesions between tissues, and/or the inadvertent inclusion of areas of
necrosis or normal glandular tissue in the ROI, causing elevated
ADC estimates. Moreover, the residual presence of blood and/or
oedema in the lesions biopsied before MRI could have caused el-
evated ADC values.
We were able to demonstrate that the choice of b-values affects
ADC estimates for breast lesions, in agreement with previous
studies.15,25 In this context, it is important to consider the dif-
ferent factors at play when choosing both the minimum and
maximum b-values, which are now further detailed.
Baron et al42 showed that the contribution of microperfusion is low
in normal breast tissue. However, in malignant processes, angio-
genesis is increased to supply tumour growth needs.43 It is therefore
expected that microperfusion effects associated with tumour
growth are higher than those observed in normal glandular
tissue. Considering that the ADC value is based on the fitting of SI
between two or more b-values, the attenuation of SI is also de-
pendent on this microperfusion effect. At low b-values, micro-
perfusion increases the ADC as observed by Peters et al,26 and to
reduce these effects, the minimum b-value in this study was set to
50 smm22. Although the perfusion contribution was therefore
most likely small on our ADC estimates, it is still possible that
some contamination effects still remained. To completely remove
this effect, some authors suggest the use of minimum b-values
ranging from 100 to 300 smm22.23,44
Similarly, the choice of maximum b-value is also very important.
It affects both the accuracy of ADC estimates and lesion conspi-
cuity.23 Provided a sufficiently high b-value is used, signal from
normal glandular tissue can be suppressed, with lesions becoming
more easily seen. Unfortunately, increasing the maximum b-value
requires longer TE, resulting in a lower SNR. Since large b-values
were included in this study (2000 and 3000 smm22), the number
of excitations were increased to compensate for potential SNR
losses. Our measured ADC values were similar to those reported
in the literature,29,38 which is consistent with adequate SNR levels.
Other factors that may affect the ADC estimates are the mathe-
matical model used, and the type of lesions included in the study.
Our data were acquired and mean SI measured using com-
mercial software provided by the manufacturer. Since there
Table 5. Mean apparent diffusion coefficient (ADC) values by histological type for ADCall and the pair combinations of b-values 50,
1000 and 200, 800smm22
Histological
type
n
ADC
(310 3mm2 s21)
50–1000a,b,
mean6 SD
ADC
(310 3mm2 s21)
50, 1000c,a,
mean6 SD
ADC
(310 3mm2 s21)
200, 800c,b,
mean6 SD
p-valuec p-valuea p-valueb
Ductal Ca in situ 9 1.336 0.70 1.356 0.69 1.306 0.76 0.68 0.31 0.95
Invasive ductal
Ca
47 1.056 0.40 1.056 0.40 1.066 0.40 0.75 0.51 0.55
Lobular Ca in
situ
4 1.096 0.19 1.106 0.20 1.056 0.20 0.07 0.14 0.07
Invasive lobular
Ca
20 1.306 0.49 1.276 0.45 1.306 0.43 0.12 0.06 0.44
Mucinous Ca 1 1.47 1.38 1.39 _ _ _
Other
malignantd
8 1.216 0.60 1.196 0.60 1.236 0.61 0.58 0.21 0.89
Fibroadenoma 24 1.806 0.36 1.786 0.37 1.816 0.38 0.46 0.32 0.77
Epithelial
proliferative
7 2.036 0.39 2.006 0.36 2.056 0.36 0.06 0.18 0.87
Papilloma 3 1.476 0.11 1.456 0.08 1.476 0.09 0.11 0.59 1.00
Hamartoma 2 1.856 0.48 1.826 0.43 1.926 0.60 0.65 0.65 0.65
Other benigne 13 1.716 0.39 1.736 0.39 1.706 0.42 0.46 0.51 0.75
Ca, carcinoma; n, number of lesions; SD, standard deviation.
a
The p-value difference in mean ADC between ADCall and the pair 50, 1000smm
22 by lesion histological type (Wilcoxon test).
b
The p-value difference in mean ADC between ADCall and the pair 200, 800smm
22 by lesion histological type (Wilcoxon test).
c
The p-value difference in mean ADC between the pairs 50, 1000 and 200, 800smm22 by lesion histological type (Wilcoxon test).
d
Not otherwise specified.
e
Fibrocystic changes, complex sclerosing adenosis, complex cystic lesion.
might be differences regarding how image acquisition and re-
construction is performed by different manufacturers, care must
be taken not to over generalize our results. Further studies should
therefore be performed comparing results across manufacturers.
Our study presents some limitations. Firstly, two readers drew the
ROIs in consensus, whereas only one reader usually performs it in
clinical practice. As mentioned above, the inclusion of high b-
values in our study prolonged the TE; the consequent decrease in
SNR was compensated by increasing the number of repetitions.
Secondly, the ADC of false-negative cases may have been
overestimated. A total of 38 lesions were biopsied before MRI.
Coincidently, this was true for 16 of the 20 false-negative cases
found in this study, namely 7 IDC with in situ component, 2
NOS, 6 ILC and 1 DCIS. In these cases, it is possible that the
presence of blood and/or oedema could have led to increased
ADC values, even if a minimum interval of 10 days was enforced
between the biopsy and the subsequent MRI examination. In
our breast unit, when lesions present highly suspicious char-
acteristics (in mammography and/or echography) the pro-
cedure adopted is to perform biopsy before breast MRI. A
future study should include a later MRI examination to help
determine the minimum period required to avoid such false
negatives. Another issue that could explain the observed ADC
increase is the partial volume effect that may occur as a result of
the slice thickness or the involuntary inclusion of areas of ne-
crosis within the ROI.
Figure 3. A 41-year-old female with suspected malignant lesion in the left breast (arrows). Sagittal short tau inversion recovery
(a) shows a large lesion, slightly hypointense in comparison with the normal fibroglandular tissue, with intense gadolinium
enhancement on the axial dynamic contrast-enhanced acquisition (b). This lesion (c) shows hyperintense signal in the sagittal
diffusion-weighted image (b-value, 1000 s mm22). The apparent diffusion coefficient (ADC) map (d) shows a hypointense lesion
(mean ADC value, 0.664 3 1023 mm2 s21). Histological diagnosis: invasive ductal carcinoma, Grade III.
an ADC threshold of 1.463 1023mm2 s21, were 77.5%, 77.6%
and 77.5%, respectively.
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